Company Overview
-
14+
R&D Pipelines
-
120+
R&D Researchers
-
110+
Patents /Patent Applications
-
3+
Technology Platforms
Sciwind Biosciences is a clinical-stage biopharmaceutical company on the cusp of commercialization, dedicated to discovering, developing, and delivering innovative therapeutics to address the unmet needs in weight management, with a clear commitment to serving patients worldwide. The company is headquartered in Hangzhou, with its R&D center located in Beijing. It has also established wholly-owned subsidiaries in Australia and the United States, which are responsible for overseas clinical development, regulatory affairs, and business development (BD) activities, respectively.
Based on SciwindCoreTM platforms, Sciwind Biosciences has established a robust pipeline of innovative drugs across various stages of development. The company has secured multiple clinical trial approvals and achieved a key milestone with two of New Drug Applications (NDAs) accepted for review by the National Medical Products Administration (NMPA). Concurrently, Sciwind is also advancing the global clinical development strategy.
The entrepreneurial team, R&D pipeline, and development capabilities of Sciwind Biosciences have been recognized by multiple prestigious investment institutions, including Tencent, IDG Capital, Meituan, LYFE Capital, Loyal Valley Capital, Lilly Asia Venture, Legend Capital, Shiyu Capital, and Haibang Investment, providing effective financial support for long-term development.
Guided by an open and collaborative strategy, Sciwind Biosciences is actively advancing internal R&D programs while seeking worldwide partnerships through out-licensing, aiming to accelerate the delivery of innovative and accessible treatments to patients worldwide, addressing urgent medical needs with both speed and affordability.
Mission
Leadship
Founder, Chairman & CEO
Hai Pan, Ph.D.
Dr. Pan is the founder, Chairman, executive Director, and general manager of our Company. He is a seasoned entrepreneur in the pharmaceutical industry with over 20 years of experience in drug development. During his nearly nine years as the principal scientist at Amgen Inc., a world-leading biotechnology company, Dr. Pan engaged in CMC development of biologics. After founding our Group, Dr. Pan and his teams advanced our Company's lead asset, ecnoglutide, to BLA submission. Over the same period, Dr. Pan led efforts to raise approximately RMB2.2 billion across seven rounds of private financing and built a team of over 150 personnel.
Dr. Pan has published numerous papers in renowned scientific journals including The Lancet Diabetes & Endocrinology (Lancet D&E), Nature Communications, and the Journal of the American Chemical Society (JACS).
Dr. Pan obtained his bachelor’s degree from Nanjing University in the PRC and doctoral degree in chemistry from The University of Nebraska-Lincoln in the U.S.
Chief Scientific Officer
Xinle Wu, Ph.D.
Dr. Wu Xinle has served as Chief Scientific Officer since January 2021, bringing over 25 years of experience in the pharmaceutical and biotechnology industries. He joined Amgen Inc., a leading Nasdaq-listed biotechnology company, serving as Principal Scientist from 2005 to 2012. From 2012 to 2019, Dr. Wu held successive leadership roles as Director and Senior Director at Lilly (China) Research and Development Co., Ltd. He subsequently served as Chief Scientific Officer at Beijing QL Biopharmaceutical Co., Ltd. from 2019 to 2020.
Dr. Wu earned his bachelor’s degree in Biophysics from Fudan University in China and his Ph.D. in Biochemistry from Case Western Reserve University in the United States.
Milestones
2025
Initiated the Phase I clinical trial for XW003 for adolescent obesity in China
2024
Entered into a license and collaboration agreement with inno.N for further development and commercialization of XW003 in Korea
Entered into a license and collaboration agreement with Sino Biopharm
Primarily completed the Phase I clinical trial for XW004 for obesity in Australia
Completed the Phase III clinical trial for obesity and T2DM for XW003 in China
2023
Initiated the Phase III clinical trial for XW003 for T2DM
Initiated the Phase III clinical trial for XW003 for obesity
2022
Initiated the Phase I clinical trial for XW004 for obesity in Australia
Initiated the Phase I clinical trial for XW014 in the United States
2021
Initiated the Phase II clinical trial for XW003 for T2DM in China
Initiated the Phase II clinical trial for XW003 for obesity in Australia
2020
Initiated the Phase I clinical trial for XW003 for obesity indication in Australia
Obtained the clinical trial approval for XW003 for both T2DM and obesity indications in China
2018
Established Beijing R&D Center
2017
Established in the PRC by PAN Hai, Ph.D.
